RDHL supply chain intelligence for RedHill Biopharma Ltd.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
RedHill Biopharma Ltd. (RDHL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CUMBERLAND | CUMBERLAND | 90% | Net revenues from U.S. sales of Talicia ® are received at the level of Talicia Holdings and are shared equally between Talicia Holdings and Cumberland pursuant to the Exclusive Joint Commercializatio… |
| BHC | Bausch Health Companies Inc. | 72% | Reciprocal relationship from BHC graph: Reciprocal relationship from RDHL graph: (Prevacid ® ) and branded and generic, prescription and OTC esomeprazole magnesium (Nexium ® ). Prescription dexlansop… |
| BHC | Bausch Health Companies Inc. | 72% | (Prevacid ® ) and branded and generic, prescription and OTC esomeprazole magnesium (Nexium ® ). Prescription dexlansoprazole (Dexilant ®, marketed by Takeda Pharmaceuticals) is the only other PPI oth… |
| GILD | Gilead Sciences, Inc. | 72% | -content imaging assays, provided further support for activities of Redhill candidates against these viral diseases. 96 Table of Contents In December 2023, we announced opaganib and RHB-107 demonstra… |
| GILD | Gilead Sciences, Inc. | 72% | Reciprocal relationship from GILD graph: Reciprocal relationship from RDHL graph: Reciprocal relationship from GILD graph: Reciprocal relationship from RDHL graph: Reciprocal relationship from GILD g… |
| GRTXD | GRTXD | 72% | Reciprocal relationship from GRTXD graph: Reciprocal relationship from RDHL graph: Reciprocal relationship from GRTXD graph: Reciprocal relationship from RDHL graph: x Pharmaceuticals Inc. (now Valea… |
| GRTXD | GRTXD | 72% | x Pharmaceuticals Inc. (now Valeant), following the black box warning received from the FDA, sales in 2009 of these products declined by 39% compared to 2008. A leading product among the PEG 3350 fam… |
| JAGX | Jaguar Health, Inc. | 72% | (Prevacid ® ) and branded and generic, prescription and OTC esomeprazole magnesium (Nexium ® ). Prescription dexlansoprazole (Dexilant ®, marketed by Takeda Pharmaceuticals) is the only other PPI oth… |
| JAGX | Jaguar Health, Inc. | 72% | Reciprocal relationship from JAGX graph: Reciprocal relationship from RDHL graph: Reciprocal relationship from JAGX graph: Reciprocal relationship from RDHL graph: (Prevacid ® ) and branded and gener… |
| ORANY | ORANY | 72% | and in each case substantially consistent with industry practices. RedHill U.S. will receive payment of fees for each service type, calculated as a specified FTE rate plus out-of-pocket costs and pas… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from RDHL graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from RDHL graph: Reciprocal relationship from ORAN… |
| PHAT | Phathom Pharmaceuticals, Inc. | 72% | Reciprocal relationship from PHAT graph: Reciprocal relationship from RDHL graph: Reciprocal relationship from PHAT graph: Reciprocal relationship from RDHL graph: Reciprocal relationship from PHAT g… |
| VTYX | Ventyx Biosciences Inc | 72% | Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc., Pfizer Inc., Protagonist Therapeutics, Inc., Theravance Biopharma, Inc., Pandio… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TALICIA-HOLDINGS-INC | TALICIA-HOLDINGS-INC | 90% | Net revenues from U.S. sales of Talicia ® are received at the level of Talicia Holdings and are shared equally between Talicia Holdings and Cumberland pursuant to the Exclusive Joint Commercializatio… |
| GRTXD | GRTXD | 72% | x Pharmaceuticals Inc. (now Valeant), following the black box warning received from the FDA, sales in 2009 of these products declined by 39% compared to 2008. A leading product among the PEG 3350 fam… |
| GRTXD | GRTXD | 72% | Reciprocal relationship from GRTXD graph: Reciprocal relationship from RDHL graph: x Pharmaceuticals Inc. (now Valeant), following the black box warning received from the FDA, sales in 2009 of these … |
| JAGX | Jaguar Health, Inc. | 72% | the marketed product from the market; · withdrawal of the therapeutic candidate from use in a clinical trial; · suspension or withdrawal of regulatory approvals; · refusal to approve pending applicat… |
| JAGX | Jaguar Health, Inc. | 72% | Reciprocal relationship from JAGX graph: Reciprocal relationship from RDHL graph: the marketed product from the market; · withdrawal of the therapeutic candidate from use in a clinical trial; · suspe… |
| ORANY | ORANY | 72% | nc. expects to purchase the inventory, in the regular course of business, as part of its ongoing commercialization of Movantik ® . Under the terms of the License Agreement, RedHill Inc. assumes res… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from RDHL graph: nc. expects to purchase the inventory, in the regular course of business, as part of its ongoing commercialization o… |
| PHAT | Phathom Pharmaceuticals, Inc. | 72% | Reciprocal relationship from PHAT graph: ribution 53 capabilities in 2021 in advance of the planned commercialization of VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, due to approval and launc… |
| VTYX | Ventyx Biosciences Inc | 72% | Reciprocal relationship from VTYX graph: Reciprocal relationship from RDHL graph: Reciprocal relationship from VTYX graph: ls N.V., Landos Biopharma, Inc., Merck & Co., Inc., Morphic Therapeutic, Inc… |
| BECAUSE-TALICIA-HOLDINGS | BECAUSE-TALICIA-HOLDINGS | 62% | acturing, quality and supply of Talicia ® , bearing the related cost of goods sold. Cumberland will oversee trade operations and distribution and fund significant commercialization activities approve… |
| CUMBERLAND-TALICIA-HOLDINGS | CUMBERLAND-TALICIA-HOLDINGS | 62% | ercialization of Talicia ® in the United States and globally and our business, financial condition and results of operations. 14 Table of Contents The division of responsibilities between Talicia Hol… |
| GAELAN-MEDICAL-TRADE-LLC | GAELAN-MEDICAL-TRADE-LLC | 62% | ted under other expenses in the Consolidated Statements of Comprehensive Income (Loss) as part of the results from discontinued operations. In addition, the Company gained full control over $ 0.7 mil… |
| KUKBO-CO-LTD | KUKBO-CO-LTD | 62% | ted under other expenses in the Consolidated Statements of Comprehensive Income (Loss) as part of the results from discontinued operations. In addition, the Company gained full control over $ 0.7 mil… |
| PRICEWATERHOUSECOOPERS-INTERNATIONAL-LIMITED | PRICEWATERHOUSECOOPERS-INTERNATIONAL-LIMITED | 62% | current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are mate… |
| TALICIA-HOLDINGS | TALICIA-HOLDINGS | 62% | acturing, quality and supply of Talicia ® , bearing the related cost of goods sold. Cumberland will oversee trade operations and distribution and fund significant commercialization activities approve… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| RDHL-DEBT | Debt stack $1.1M | 90% | Market cache reports total debt of $1.1M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| RDHL-OWNER-YORKVILLE-ADVISORS-GLOBAL-LP | Yorkville Advisors Global, LP | 90% | 13F overlay lists Yorkville Advisors Global, LP as top holder; 17 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 100.00 | 1 | ['supplier'] |
| JAGX | Jaguar Health, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| PHAT | Phathom Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BHC | Bausch Health Companies Inc. | 100.00 | 1 | ['supplier'] |
| GRTXD | Galera Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| VTYX | Ventyx Biosciences Inc | 100.00 | 1 | ['customer', 'supplier'] |
| CAH | Cardinal Health, Inc. | 50.00 | 2 | |
| ALC | Alcon Inc. | 50.00 | 2 | |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 50.00 | 2 | |
| BLCO | Bausch + Lomb Corporation | 50.00 | 2 | |
| CABA | Cabaletta Bio, Inc. | 50.00 | 2 | |
| SDGR | Schrödinger, Inc. | 50.00 | 2 | |
| AGEN | Agenus Inc. | 50.00 | 2 | |
| SLGL | Sol-Gel Technologies Ltd. | 50.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 50.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 50.00 | 2 | |
| CRIS | Curis, Inc. | 50.00 | 2 | |
| ORANY | ORANGE | 50.00 | 2 | ['customer', 'supplier'] |
| CAPT | Captivision Inc | 50.00 | 2 | |
| CGEN | Compugen Ltd. | 50.00 | 2 |